SUTRO BIOPHARMA, INC. Gain (Loss) on Disposition of Assets
SUTRO BIOPHARMA, INC. (STRO) reported Gain (Loss) on Disposition of Assets of -$275.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-16.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfAssets1 · last filed 2020-03-16
- SUTRO BIOPHARMA, INC. gain (loss) on disposition of assets for the quarter ending 2019-12-31 was $20.00K.
- SUTRO BIOPHARMA, INC. gain (loss) on disposition of assets for the quarter ending 2019-09-30 was -$52.00K.
- SUTRO BIOPHARMA, INC. gain (loss) on disposition of assets for the quarter ending 2018-09-30 was $0.00.
- SUTRO BIOPHARMA, INC. gain (loss) on disposition of assets for fiscal 2019 was -$275.00K.
| Period end | Gain (Loss) on Disposition of Assets 3 month | Gain (Loss) on Disposition of Assets 6 month | Gain (Loss) on Disposition of Assets 9 month | Gain (Loss) on Disposition of Assets 12 month |
|---|---|---|---|---|
| 2019-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$32.00K derived: sum of 2 quarters · filed 2020-03-16 | -$275.00K 10-K · filed 2020-03-16 | |
| 2019-09-30 | -$52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$295.00K 10-Q · filed 2019-11-08 | ||
| 2019-06-30 | -$243.00K 10-Q · filed 2019-08-14 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$35.00K 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | -$35.00K 10-Q · filed 2019-08-14 | |||
| 2017-09-30 | -$87.00K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |